Related Experiment Video
Updated: Jun 25, 2026

Guidelines for Elective Pediatric Fiberoptic Intubation
Published on: January 17, 2011
Prophylactic pharmacological interventions against perioperative respiratory adverse events in children undergoing
Qi-Wen Deng1, Wen-Cheng Tan2, Ya-Qing Zhan1
1Department of Anesthesiology, the First Affiliated Hospital, Sun Yat-sen University, No.58, Zhongshan 2Nd Road, Guangzhou, 510080, China.
Insights
This meta-analysis shows that lidocaine, dexmedetomidine, beta2-adrenoreceptor agonists, and propofol induction can help prevent perioperative respiratory adverse events (PRAE) in children. However, results should be interpreted cautiously due to varied definitions of PRAE.
Area of Science:
- Anesthesiology
- Pediatric Surgery
- Pharmacology
Background:
- Perioperative respiratory adverse events (PRAE) are common in pediatric anesthesia.
- Effective prevention strategies are crucial for patient safety during noncardiac surgery.
Purpose of the Study:
- To evaluate the efficacy of perioperative pharmacological interventions in preventing PRAE in pediatric patients undergoing noncardiac surgery.
- To synthesize evidence from randomized controlled trials (RCTs) on prophylactic treatments for PRAE.
Main Methods:
- A comprehensive literature search was conducted across PubMed, Embase, Cochrane Library, and ClinicalTrials.gov for RCTs.
- Pairwise meta-analyses were performed to compare interventions against placebo or other treatments for overall PRAE and specific subtypes.
- Risk of bias was assessed using the Cochrane Collaboration tool.
Main Results:
- Twenty-nine RCTs involving 4452 children were included.
- Lidocaine, dexmedetomidine, and beta2-adrenoreceptor agonists demonstrated significant reductions in overall PRAE and specific events like laryngospasm and coughing compared to placebo.
- Intravenous propofol induction was associated with lower odds of PRAE, laryngospasm, and airway obstruction compared to sevoflurane induction.
Conclusions:
- Lidocaine, dexmedetomidine, beta2-adrenoreceptor agonists, and propofol induction show prophylactic potential against PRAE in pediatric surgery.
- Caution is advised due to inconsistent definitions of PRAE and potential correlations among subtypes.
Purpose:
Perioperative respiratory adverse event (PRAE) is one of the most common complications in pediatric anesthesia. We aimed to evaluate the efficacy of perioperative pharmacological interventions to prevent the development of PRAE in children undergoing noncardiac surgery.
Methods:
PubMed, Embase, Cochrane Library and ClinicalTrials.gov were searched for randomized controlled trials (RCT) of prophylactic pharmacological interventions for PRAE among surgical children from inception to 5 August 2024. Pairwise meta-analyses were conducted to compare the effects of an intervention with placebo or another intervention on overall PRAE and their subtypes, including laryngospasm, bronchospasm, oxygen desaturation, airway obstruction, coughing and stridor. Risk of bias was assessed using the Cochrane Collaboration tool.
Results:
Seven categories of prophylactic interventions were identified. Twenty-nine RCTs with 4452 children were included. Compared with placebo, lidocaine reduced the odds ratio (OR) of overall PRAE ( 0.27 [95% CI] [0.17, 0.42]) and laryngospasm (0.38 [0.22, 0.67]); dexmedetomidine reduced the OR of PRAE (0.31 [0.12, 0.76]), laryngospasm (0.31 [0.10, 0.91]), coughing (0.24 [0.14, 0.41]) and oxygen desaturation (0.54 [0.35, 0.84]); β2-adrenoreceptor agonists reduced the OR of PRAE (0.45 [0.24, 0.83]), coughing (0.36 [0.13, 0.95]) and oxygen desaturation (0.66 [0.45, 0.98]). Compared with sevoflurane induction, intravenous propofol induction lowered the OR of PRAE (0.35 [0.16, 0.74]), laryngospasm (0.17 [0.06, 0.48]) and airway obstruction (0.32 [0.17, 0.63]).
Conclusions:
The meta-analysis demonstrated prophylactic potential of lidocaine, dexmedetomidine, β2-adrenoreceptor agonists and propofol induction technique against PRAE, but it should be interpreted cautiously due to inconsistent PRAE definition and correlation of subtypes within the composite outcome.
Trial Registration:
PROSPERO (CRD42020220028). Registered 11 December 2020. Updated 3 September 2024.
Related Concept Videos
Respiratory Assessment: Purpose and Indications
Objectives and Importance:
The primary goal of respiratory assessment is to evaluate patients at early risk of clinical deterioration. Since respiratory distress often precedes other signs of declining health, breathing patterns and sounds become a...
Skeletal Muscle Relaxants: Therapeutic Uses
Inhalational Anesthetics: Overview
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Suctioning the Nasopharyngeal Airway
Equipment Required

